|
 |
| |
| |
| Licensing & Royalties >> Licensing Opportunities >> Abstract Details |
|
| |
| Synthetic Analogs of Juxtamembrane Domain of IGF-1 Receptor as Anti-Cancer Agents |
Description of Invention:
Insulin-like growth factor receptor type one (IGF-1R), part of the receptor tyrosine kinase (RTKs) family, is integral to cancer cell growth and metastasis. Juxtamembrane domains (JM) of RTKs are located in the cytoplasm between the transmembrane and kinase domains. JMs play a crucial role in the inhibition of the regulation of receptor activity. Studies on other small molecules tyrosine kinase inhibitors (TKIs) indicate non-specific binding with the insulin receptor which has high homology with IGF-1R.
The current invention describes synthetic analogs of IGF-1R JM which were found to be potent inhibitors of IGF-1-mediated cell signaling and cancer cell growth. These analogs provide more binding specificity with less likelihood of significant toxic effects.
Applications:
- New inhibitors can be used to treat many types of tumors.
- IGR-1R inhibition may be useful as an anti-aging agent.
- IGR-1R plays an inhibitory role in regulation of skin development and differentiation. IGF-1R inhibitors may have revitalizing and rejuvenating effect on skin and may stimulate wound healing.
Development Status:
The technology is currently in the preclinical stage of development.
Inventors:
Nadya I Tarasova (NCI)
Sergey G Tarasov (NCI)
Patent Status:
HHS, Reference No. E-129-2008/0
US, Application No. 12/934,911 filed 27 Sep 2010
Licensing Status:
Available for exclusive and non-exclusive licensing.
For Licensing Information Please Contact:
Jennifer Wong
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: wongje@mail.nih.gov
Phone: 301-435-4633
Fax: 301-402-0220
Ref No: 1753
Updated: 05/2008
|
|
|
|
| |
|
|
|
|